TriangleFOR PATIENTS · SOURCE READING
Treatment of Recurrent Acute Lymphoblastic Leukemia
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Treatment of recurrent ALL may include:
Source links and citations
combination chemotherapy followed by stem cell transplant
Source links and citations
immunotherapy (blinatumomab or inotuzumab ozogamicin) followed by stem cell transplant
Source links and citations
low-dose radiation therapy as palliative care to relieve symptoms and improve quality of life
Source links and citations
targeted therapy with dasatinib or revumenib for certain patients
Source links and citations
CAR T-cell therapy (brexucabtagene autoleucel or tisagenlecleucel) for certain patients
Source links and citations
Some of the treatments being studied in clinical trials for recurrent ALL include stem cell transplant using the patient's stem cells.
Source links and citations
Learn more about these treatments in the Treatment Option Overview.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice